Responding to a rebuttal letter concerning the BERVOLT study

Graefes Arch Clin Exp Ophthalmol. 2016 May;254(5):1025-6. doi: 10.1007/s00417-015-3217-6. Epub 2015 Nov 19.

Authors

Tom Kornhauser¹, Adiel Barak²

Affiliations

¹ The Soroka University Medical Center, Ben Gurion University of the Negev, Beer Sheva, Israel. tomchook@gmail.com.
² Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

PMID: 26582162
DOI: 10.1007/s00417-015-3217-6

No abstract available

Keywords: Bevacizumab; Branch retinal vein occlusion; Central retinal vein occlusion; Retinal vein occlusion.

Publication types

Letter
Comment

MeSH terms

Angiogenesis Inhibitors
Bevacizumab
Follow-Up Studies
Humans
Macular Edema*
Retinal Vein Occlusion*

Substances

Angiogenesis Inhibitors
Bevacizumab